We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
TTPH, Tetraphase Pharmaceuticals
An SI Board Since January 2016
Posts SubjectMarks Bans Symbol
81 20 0 TTPH
Emcee:  scaram(o)uche Type:  Moderated
Tetraphase has hit a snag, failing inferiority testing with an antibiotic at phase III. The company should be considered as having two phase I clinical trial programs, with one of those molecules having passed a single phase III trial. Current plans are to file in Europe for eravacycline, but it's back to phase I for the U.S.

Last share offering, 3/15, was at $35.

Current shares (1/28/16) are going for $5.18.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
81U.S. FDA approves Tetraphase Pharma's antibiotic Wong-8/30/2018
80Bullish crossover in MACD and Stochastic oscillator. Looking for breakout at 3.Alejandroo Green-8/6/2018
79I never take my due from class action suits. Last one I participated in was Elascaram(o)uche-7/31/2018
78Yup. I'd be more interested in this for its remaining early stage programs,tuck-2/15/2018
77When it happens twice in 18 months it's hard to make the argument that managHardToFind-2/15/2018
76Here’s What’s Moving Tetraphase Tetraphase Pharmaceuticals, Inc. ( NASDAQ:TTPH)HardToFind-2/14/2018
75So with the Eravacycline program presumably dead, does the remaining pipe look ctuck-2/13/2018
74Sadly, every poorly managed public company will do the same. Only the well managHardToFind-1/23/2018
73What would it take for someone on the Board to say..... "No, no, no, no....scaram(o)uche-1/23/2018 What wouscaram(o)uche21/23/2018
71Motley Fool article that includes a favorable discussion of TTPH: finance.yahooHardToFind-1/16/2018
70From 200 to 250. Twice a day.gcrispin-12/21/2017
69What was the dosage change? Did they say?HardToFind-12/20/2017
68Thanks. Also a higher dosage. Obviously didn’t do enough testing the first tigcrispin-12/20/2017
67I gather from the 14 Dec 2017 BMO presentation, it seems as though the new oralHardToFind-12/18/2017
66The Latest Press Release On Oral Dosing (11/2/2017): Presented data at IDWeek 2HardToFind-11/5/2017
65Good to know the chatter, thanks.scaram(o)uche-10/9/2017
64...suggesting compliance would be difficult with TID dosing. Not sure how that wHardToFind-10/5/2017
63Saw a tweet concerned with food effect, suggesting compliance would be difficulttuck-10/5/2017 Show you how important the oral has always been to this stock.gcrispin110/4/2017
61Looks like there is a route forward, with modest development time frames. 80%scaram(o)uche-10/4/2017
60Gotcha. Plazomicin is my interest here. Building a modest position in AKAO. Setuck-9/20/2017
59Omadacycline is a tetracycline. So, yes, I watch it as a direct competitor, marscaram(o)uche-9/20/2017
58targets the 30S subunit of the bacterial ribosome. Actually, so do the efforts ftuck-9/19/2017
57Competing program . . . It is my understanding that 271 targets the 30Stuck-9/19/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):